Data Sheet (Cat.No.T5139)



CZC-25146 hydrochloride

Chemical Proper	ties	
CAS No. :	1330003-04-7	H ₃ C _ S
Formula:	C22H26ClFN6O4S	
Molecular Weight:	525 MCI	
Appearance: 🦲	no data available	
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year	└°

Biological Description

Description	CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.
Targets(IC50)	LRRK2
In vitro	CZC-25146 inhibited only five kinases(PLK4, GAK, TNK1, CAMKK2, and PIP4K2C) with high potency. CZC-25146 neither caused cytotoxicity in human cortical neurons at concentrations below 5 μ M over a seven-day treatment in culture nor did it block neuronal development in vitro.
In vivo	CZC-25146 possesses favorable pharmacokinetic properties, such as a volume of distribution of 5.4 L/kg and clearance of 2.3 L/hr/kg that render it suitable for in-vivo studies.

n		
DMSO: 55 mg/mL (104.76 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)	Ċ	

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9048 mL	9.5238 mL	19.0476 mL
5 mM	0.381 mL	1.9048 mL	3.8095 mL
10 mM	0.1905 mL	0.9524 mL	1.9048 mL
50 mM	0.0381 mL	0.1905 mL	0.381 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ramsden N, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8.

Inhibitor • Natural Compounds • Compound Libraries • Recombinant Proteins This product is for Research Use Only• Not for Human or Veterinary or Therapeutic Use Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481